Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01360840




Registration number
NCT01360840
Ethics application status
Date submitted
15/04/2011
Date registered
26/05/2011
Date last updated
14/12/2015

Titles & IDs
Public title
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
Scientific title
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Secondary ID [1] 0 0
EMR 62242-006
Universal Trial Number (UTN)
Trial acronym
PERSEUS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Prostate Cancer Metastatic 0 0
Condition category
Condition code
Cancer 0 0 0 0
Prostate

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - EMD 525797
Treatment: Drugs - EMD 525797
Other interventions - Placebo
Other interventions - Standard of Care (SoC)

Placebo comparator: Placebo + Standard of care (SoC) -

Experimental: EMD 525797 750 mg + SoC -

Experimental: EMD 525797 1500 mg + SoC -


Treatment: Drugs: EMD 525797
Subjects will be administered with EMD 525797 at a dose of 1500 milligram (mg) (diluted with 0.9 percent \[%\] sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.

Treatment: Drugs: EMD 525797
Subjects will be administered with EMD 525797 at a dose of 750 mg (diluted with 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.

Other interventions: Placebo
Subjects will be administered with placebo (as 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.

Other interventions: Standard of Care (SoC)
All the subjects followed the SoC consisting of the continued treatment with luteinizing-hormone releasing hormone agonists (or antagonists).
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression Free Survival (PFS) Time
Timepoint [1] 0 0
Time from randomization until data cut-off date (30 April 2013), assessed up to 2 years
Secondary outcome [1] 0 0
Overall Survival
Timepoint [1] 0 0
Time from randomization until data cut-off date (30 April 2013), assessed up to 2 years
Secondary outcome [2] 0 0
Time to Tumor Progression
Timepoint [2] 0 0
Time from randomization until data cut-off date (30 April 2013), assessed up to 2 years
Secondary outcome [3] 0 0
Number of Subjects With Presence of Tumor Response and Disease Control (DC) in Soft Tissue Lesions
Timepoint [3] 0 0
Time from randomization until data cut-off date (30 April 2013), assessed up to 2 years
Secondary outcome [4] 0 0
Number of Subjects With New Bone Lesions Compared to Baseline
Timepoint [4] 0 0
Time from randomization until data cut-off date (30 April 2013), assessed up to 2 years
Secondary outcome [5] 0 0
Number of Subjects With Presence of DC in Bone Lesions
Timepoint [5] 0 0
At Weeks 13, 19 and 25
Secondary outcome [6] 0 0
Bone and Soft Tissue Lesions Composite Tumor Response
Timepoint [6] 0 0
Time from randomization until data cut-off date (30 April 2013), assessed up to 2 years
Secondary outcome [7] 0 0
Number of Subjects With Presence of Skeletal Related Events
Timepoint [7] 0 0
Time from randomization until data cut-off date (30 April 2013), assessed up to 2 years
Secondary outcome [8] 0 0
Number of Subjects With Presence of Prostate Specific Antigen (PSA) Response
Timepoint [8] 0 0
Time from randomization until data cut-off date (30 April 2013), assessed up to 2 years
Secondary outcome [9] 0 0
Minimum Percentage Change From Baseline in PSA Serum Concentration
Timepoint [9] 0 0
Baseline, up to data cut-off date (30 April 2013), assessed up to 2 years
Secondary outcome [10] 0 0
Minimum Percentage Change From Baseline in the Number of Circulating Tumor Cells (CTCs)
Timepoint [10] 0 0
Time from randomization until data cut-off date (30 April 2013), assessed up to 2 years
Secondary outcome [11] 0 0
Overall Minimum Percentage Change From Previous Time Point in Circulating Tumor Cells (CTC)
Timepoint [11] 0 0
Cycle 1, Day 1 (Week 1): pre-dose, Cycle 3, Day 1 (Week 7): pre-dose, and Cycle 5, Day 1 (Week 13): pre-dose
Secondary outcome [12] 0 0
Number of Subjects With Any Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death, and TEAEs Leading to Discontinuation
Timepoint [12] 0 0
From the first dose of study drug administration until 50 days after the last dose of study drug administration or until cut-off date (30 April 2013), assessed up to 2 years
Secondary outcome [13] 0 0
Pharmacokinetic Parameter: Clearance of Intravenously Administered EMD 525797 After First Dose (CL) and Clearance in Steady State of EMD52597 After Fifth Dose (CLss)
Timepoint [13] 0 0
Cycle 1 (Week 1) and cycle 5 (Week 13): Day 1: pre-dose, End of Infusion (EOI), 4, 8, 24, 48, 96, 168, 336, and 504 hours after start of infusion; Cycles 3 and 4 (Weeks 7 and 10), Day 1: pre-dose; Cycle 7 (Week 19), Day 1: pre-dose and EOI
Secondary outcome [14] 0 0
Pharmacokinetic Parameter: Volume of Distribution of EMD 525797 After the First Dose (V) and in Steady State After the Fifth Dose (Vss) of Intravenous Infusion
Timepoint [14] 0 0
Cycle 1 (Week 1) and cycle 5 (Week 13): Day 1: pre-dose, End of Infusion (EOI), 4, 8, 24, 48, 96, 168, 336, and 504 hours after start of infusion; Cycles 3 and 4 (Weeks 7 and 10), Day 1: pre-dose; Cycle 7 (Week 19), Day 1: pre-dose and EOI

Eligibility
Key inclusion criteria
* Histologically or cytologically confirmed adenocarcinoma of the prostate (Gleason score)
* Bisphosphonate treatment
* Stable, ongoing adequate testosterone suppression proven by hypogonadal levels of testosterone (less than or equal to) <= 50 nanogram per deciliter [ng/dL]) for subjects without surgical castration (luteinizing hormone-releasing hormone antagonists and agonists)
* Other protocol defined inclusion criteria could apply
Minimum age
18 Years
Maximum age
No limit
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
* Prior chemotherapy, biologic therapy (targeted therapy), or any experimental therapy for mCRPC
* Chronic and ongoing treatment with opioids
* Acute pathologic fracture, spinal cord compression, or hypercalcemia at Screening
* Visceral metastasis, brain metastasis
* Radiotherapy to bone lesions and/or orthopedic surgery for pathologic fractures. Any kinds of major elective surgery within 30 days prior to trial treatment
* Other protocol defined exclusion criteria could apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/04/2011
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/07/2014
Sample size
Target
Accrual to date
Final
180
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Bendigo
Recruitment hospital [2] 0 0
Research Site - Coffs Harbour
Recruitment hospital [3] 0 0
Research Site - Darlinghurst
Recruitment hospital [4] 0 0
Research Site - Frankston
Recruitment hospital [5] 0 0
Research Site - Gosford
Recruitment hospital [6] 0 0
Research Site - Kurralta Park
Recruitment hospital [7] 0 0
Research Site - Northmead
Recruitment hospital [8] 0 0
Research Site - Port Macquarie
Recruitment hospital [9] 0 0
Research Site - Randwick
Recruitment hospital [10] 0 0
Research Site - Turnhout
Recruitment postcode(s) [1] 0 0
- Bendigo
Recruitment postcode(s) [2] 0 0
- Coffs Harbour
Recruitment postcode(s) [3] 0 0
- Darlinghurst
Recruitment postcode(s) [4] 0 0
- Frankston
Recruitment postcode(s) [5] 0 0
- Gosford
Recruitment postcode(s) [6] 0 0
- Kurralta Park
Recruitment postcode(s) [7] 0 0
- Northmead
Recruitment postcode(s) [8] 0 0
- Port Macquarie
Recruitment postcode(s) [9] 0 0
- Randwick
Recruitment postcode(s) [10] 0 0
- Turnhout
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Illinois
Country [3] 0 0
United States of America
State/province [3] 0 0
Louisiana
Country [4] 0 0
United States of America
State/province [4] 0 0
Michigan
Country [5] 0 0
United States of America
State/province [5] 0 0
New Jersey
Country [6] 0 0
United States of America
State/province [6] 0 0
Ohio
Country [7] 0 0
United States of America
State/province [7] 0 0
Texas
Country [8] 0 0
United States of America
State/province [8] 0 0
Virginia
Country [9] 0 0
United States of America
State/province [9] 0 0
Washington
Country [10] 0 0
Belgium
State/province [10] 0 0
Antwerp
Country [11] 0 0
Canada
State/province [11] 0 0
Ontario
Country [12] 0 0
Canada
State/province [12] 0 0
Abbotsford
Country [13] 0 0
Canada
State/province [13] 0 0
Province of British Columbia
Country [14] 0 0
Canada
State/province [14] 0 0
Toronto
Country [15] 0 0
Canada
State/province [15] 0 0
Victoria
Country [16] 0 0
Canada
State/province [16] 0 0
Windsor
Country [17] 0 0
France
State/province [17] 0 0
Angers
Country [18] 0 0
France
State/province [18] 0 0
Bourgogne
Country [19] 0 0
France
State/province [19] 0 0
Caen Cedex 05
Country [20] 0 0
France
State/province [20] 0 0
Colmar
Country [21] 0 0
France
State/province [21] 0 0
Paris
Country [22] 0 0
France
State/province [22] 0 0
Reims
Country [23] 0 0
France
State/province [23] 0 0
Villejuif
Country [24] 0 0
Germany
State/province [24] 0 0
Aachen
Country [25] 0 0
Germany
State/province [25] 0 0
Berlin
Country [26] 0 0
Germany
State/province [26] 0 0
Darmstadt
Country [27] 0 0
Germany
State/province [27] 0 0
Dresden
Country [28] 0 0
Germany
State/province [28] 0 0
Esslingen
Country [29] 0 0
Germany
State/province [29] 0 0
Freiburg
Country [30] 0 0
Germany
State/province [30] 0 0
Hannover
Country [31] 0 0
Germany
State/province [31] 0 0
Nürtingen
Country [32] 0 0
Germany
State/province [32] 0 0
Reutlingen
Country [33] 0 0
Germany
State/province [33] 0 0
Tübingen
Country [34] 0 0
Netherlands
State/province [34] 0 0
Blaricum
Country [35] 0 0
Netherlands
State/province [35] 0 0
Groningen
Country [36] 0 0
Netherlands
State/province [36] 0 0
Haarlem
Country [37] 0 0
Poland
State/province [37] 0 0
Gdansk
Country [38] 0 0
Poland
State/province [38] 0 0
Lublin
Country [39] 0 0
Poland
State/province [39] 0 0
Lódz
Country [40] 0 0
Russian Federation
State/province [40] 0 0
Barnaul
Country [41] 0 0
Russian Federation
State/province [41] 0 0
Ekaterinburg
Country [42] 0 0
Russian Federation
State/province [42] 0 0
Ivanovo
Country [43] 0 0
Russian Federation
State/province [43] 0 0
Izhevsk
Country [44] 0 0
Russian Federation
State/province [44] 0 0
Kazan
Country [45] 0 0
Russian Federation
State/province [45] 0 0
Krasnoyarsk
Country [46] 0 0
Russian Federation
State/province [46] 0 0
Omsk
Country [47] 0 0
Russian Federation
State/province [47] 0 0
Petersburg
Country [48] 0 0
Russian Federation
State/province [48] 0 0
Stavropol
Country [49] 0 0
Slovakia
State/province [49] 0 0
Presov
Country [50] 0 0
South Africa
State/province [50] 0 0
Gauteng
Country [51] 0 0
South Africa
State/province [51] 0 0
Kwa-Zulu Natal
Country [52] 0 0
South Africa
State/province [52] 0 0
Pretoria Gauteng
Country [53] 0 0
South Africa
State/province [53] 0 0
Western Cape
Country [54] 0 0
Spain
State/province [54] 0 0
Barcelone
Country [55] 0 0
Spain
State/province [55] 0 0
Madrid
Country [56] 0 0
Spain
State/province [56] 0 0
Pamplona
Country [57] 0 0
Spain
State/province [57] 0 0
Sabadell, Barcelone

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
EMD Serono
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective of the trial is to evaluate the clinical anti-tumor activity of EMD 525797 administered as 1-hour intravenous infusion every 3 weeks in terms of progression free survival (PFS) time in subjects with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (mCRPC).
Trial website
https://clinicaltrials.gov/study/NCT01360840
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Responsible
Address 0 0
EMD Serono Inc., an affiliate of Merck KGaA, Darmstadt, Germany
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01360840